Bausch Health Companies Inc. stands as a prominent player in Canada’s pharmaceutical and medical-device landscape, operating a diversified portfolio that spans eye health, gastroenterology, dermatology, neurology and aesthetic devices. Headquartered in Laval, Quebec, the company combines legacy brands with specialty product lines such as Bausch + Lomb eye-care solutions and gastroenterology offerings under the Salix Pharmaceuticals unit. Over the last decade Bausch Health has navigated complex restructuring ...

Core Insights - Bausch Health Companies Inc. (BHC) reported mixed results for Q2 2025, with adjusted earnings per share of 90 cents missing the Zacks Consensus Estimate of 97 cents, while total revenues of $2.53 billion exceeded expectations, marking a 5% year-over-year increase [1][7] Revenue Breakdown - Salix segment revenues reached $627 million, up 12% year over year, driven by strong demand for Xifaxan, Trulance, and Relistor, surpassing the Zacks Consensus Estimate of $589 million [3][4] - International revenues totaled $278 million, a 1% increase year over year, but fell short of estimates, with organic growth also at 1% [5] - Solta Medical reported revenues of $128 million, up 25% year over year, driven by global volume expansion, although it missed the model estimate [8] - Diversified Products revenues decreased by 13% to $219 million, with declines in neurology, generics, and dermatology segments [9][10] - Bausch + Lomb revenues amounted to $1.3 billion, a 5% increase year over year, exceeding estimates and driven by growth in the vision care segment [10] Pipeline Development - BHC is reviewing pipeline candidate amiselimod for ulcerative colitis treatment and has submitted an application for Cabtreo, which was approved in Canada [11] - Phase III studies for rifaximin are ongoing, with top-line results expected by early 2026 [12] - The Clear and Brilliant Touch program is advancing with approvals in multiple countries, and the Fraxel FTX system was launched in the U.S. in April 2025 [13][14] Financial Guidance - BHC updated its 2025 revenue guidance to a range of $10-$10.25 billion, with Bausch + Lomb revenues projected between $5.05-$5.15 billion [15] Acquisition Activity - BHC announced plans to acquire DURECT Corporation for $63 million, with potential milestone payments of up to $350 million, focusing on larsucosterol for alcoholic hepatitis treatment [17][18][19]

2Q 2025 Earnings July 30, 2025 forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or r ...